Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02451579 · ClinicalTrials.gov registry record · NA

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

A NA study of Actinic Keratoses, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT02451579: Completed NA study of Actinic Keratoses, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

NCT02451579 is a NA study of Actinic Keratoses that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02451579, a NA study of Actinic Keratoses, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.

Primary Outcome

Localized Skin Response consisting of erythema, edema, crusting, exudation, Vesiculation/Pustulation and erosion/ ulceration Investigator evaluated on a standardized scale

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Antihistamine Cetirizine Hydrochloride

Study Locations (1)

California

  • Cosmetic Laser Dermatology - San Diego

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-02
Est. Completion 2017-01
Phase NA

What the finished NCT02451579 record still lists

NCT02451579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02451579 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02451579 about?

NCT02451579 is a clinical study titled "A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy". A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.

What is the current status of trial NCT02451579?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-02. Estimated completion is 2017-01.

What conditions does trial NCT02451579 study?

This clinical trial studies the following conditions: Actinic Keratoses.

What interventions are being tested in trial NCT02451579?

The interventions under investigation include: Placebo (OTHER), Antihistamine Cetirizine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT02451579?

This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02451579 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratoses

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02451579's enrollment target sits among peer trials

20 11th of 12 higher than 1 of 12 other Actinic Keratoses trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Actinic Keratoses trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02451579, the US trial registry maintained by the National Library of Medicine. NCT02451579 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.